Overview

Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer

Status:
Unknown status
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
A multi-center, non-random, open study ,to observe efficacy and safety of bevacizumab plus Oxaliplatin based multidrug chemotherapy as conversion therapy for patients with previously untreated unresectable liver metastases from colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Liaoning Tumor Hospital & Institute
Treatments:
Bevacizumab
Capecitabine
Fluorouracil
Oxaliplatin